Literature DB >> 32321169

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.

Wenqun Zhang1, Jing Yang2, Chunju Zhou3, Bo Hu1, Ling Jin2, Biping Deng4, Yang Liu1, Shan Wang1, Alex H Chang5, Juan Du1, Zifen Gao6, Yonghong Zhang1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32321169     DOI： 10.1182/blood.2019002008

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Authors:  Emily M Hsieh; Rayne H Rouce
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.

Authors:  Samantha J Seitter; Paul H McClelland; Mark A Ahlman; Stephanie L Goff; James C Yang; Lori McIntyre; Steven A Rosenberg; James N Kochenderfer; Jennifer N Brudno
Journal:  Leuk Lymphoma       Date:  2022-06-09

3.  Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Authors:  Jiaying Wu; Yang Cao; Qi Zhang; Wanying Liu; Xiaoxi Zhou; Xi Ming; Fankai Meng; Yicheng Zhang; Chunrui Li; Liang Huang; Jia Wei; Miao Zheng; Shangkun Zhang; Tongcun Zhang; Xiaojian Zhu; Na Wang; Jue Wang; Gaoxiang Wang; Jianfeng Zhou; Bo Liu; Yi Xiao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

4.  Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.

Authors:  Biping Deng; Jing Pan; Zhaoli Liu; Shuangyou Liu; Yunlong Chen; Xiaomin Qu; Yu'e Zhang; Yuehui Lin; Yanlei Zhang; Xinjian Yu; Zhongxin Zhang; Xuansha Niu; Rong Luan; Ming Ma; Xiaomei Li; Tingting Liu; Xi'ai Wu; Huan Niu; Alex H Chang; Chunrong Tong
Journal:  Mol Ther Methods Clin Dev       Date:  2021-10-27       Impact factor: 6.698

5.  Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.

Authors:  Ying Liu; Biping Deng; Bo Hu; Wenqun Zhang; Qing Zhu; Yang Liu; Shan Wang; Pei Zhang; Ying Yang; Junhan Yang; Qinlong Zheng; Xinjian Yu; Zifen Gao; Chunju Zhou; Wei Han; Jing Yang; Ling Jin; Chunrong Tong; Alex H Chang; Yonghong Zhang
Journal:  Blood Adv       Date:  2022-02-08

Review 6.  Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.

Authors:  Ke Liu; Jia-Jia Cui; Yan Zhan; Qian-Ying Ouyang; Qi-Si Lu; Dong-Hua Yang; Xiang-Ping Li; Ji-Ye Yin
Journal:  Mol Cancer       Date:  2022-04-11       Impact factor: 27.401

Review 7.  Road testing new CAR design strategies in multiple myeloma.

Authors:  Priyanka S Rana; Elena V Murphy; Jeries Kort; James J Driscoll
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 8.  Clinical development of CAR T cell therapy in China: 2020 update.

Authors:  Jianshu Wei; Yelei Guo; Yao Wang; Zhiqiang Wu; Jian Bo; Bin Zhang; Jun Zhu; Weidong Han
Journal:  Cell Mol Immunol       Date:  2020-09-30       Impact factor: 11.530

9.  Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.

Authors:  Yuan Meng; Biping Deng; Luan Rong; Chuo Li; Weiliang Song; Zhuojun Ling; Jinlong Xu; Jiajia Duan; Zelin Wang; Alex H Chang; Xiaoming Feng; Xiujuan Xiong; Xiaoli Chen; Jing Pan
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.